Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 10/20 | 1.00 |
| ▸ | LPAR4 | Q99677 | 5/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 1.00 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 4/20 | 1.00 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 1.00 |
| ▸ | LPAR6 | P43657 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 1.00 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.72 |
| ▸ | GPR174 | Q9BXC1 | 6/20 | 0.72 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.72 |
| ▸ | DGKA | P23743 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360211 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| SCHEMBL6360208 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| SCHEMBL6349896 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| Lysophosphatidic Acid SCHEMBL1548 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| Lysophosphatidic Acid SCHEMBL3672549 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| Lysophosphatidic Acid SCHEMBL12388925 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| SCHEMBL6340952 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| SCHEMBL6349984 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| SCHEMBL6336799 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 | |
| SCHEMBL6356572 | 1.00 | LPAR1 (1.00) | LPAR1LPAR4LPAR2LPAR3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR4 3/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.